A study on patients with Barth syndrome treated with elamipretide has provided insights into metabolomic biomarkers. The study, known as the TAZPOWER study, has been referenced alongside research on various other diseases, including mitochondrial diseases, hypertension, diabetes mellitus, systemic sclerosis, and Alzheimer's disease. It is unclear how the TAZPOWER study's findings relate to these other conditions, but they may contribute to broader understanding of disease mechanisms and therapeutic approaches.